Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022

被引:5
作者
Galvez, Jubby Marcela [1 ]
Pinzon-Rondon, Angela Maria [2 ]
Chaparro-Solano, Henry Mauricio [2 ]
Tovar-Romero, Hanna Valentina [2 ]
Ramirez-Prieto, Juliana [2 ]
Ortigoza-Espitia, Sergio Andres [2 ]
Ruiz-Sternberg, Angela Maria [2 ]
机构
[1] Gencell Pharma, Genuino Res Grp, Bogota 111221, Colombia
[2] Univ Rosario, Clin Invest Grp, Carrera 24 63C-69, Bogota 111221, Colombia
基金
英国科研创新办公室;
关键词
COVID-19; booster dose; effectiveness; Colombia; vaccination strategy;
D O I
10.3390/vaccines11091461
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination has proven to be one of the most effective strategies against the COVID-19 pandemic. Several studies have evaluated and confirmed its effectiveness in different populations, particularly in reducing severe outcomes such as hospitalization and death. Some studies have investigated the effectiveness of vaccination against the infection, identifying the need for booster doses. This study aimed to explore the effectiveness of the vaccination schedule on the probability of infection in a sample of Colombian patients during the fourth wave of the COVID-19 pandemic, which was associated with the emergence and predominance of the Omicron variant. A cross-sectional study was conducted on individuals who underwent RT-PCR testing for COVID-19 detection in a dedicated laboratory in Bogota, Colombia, between 30 December 2021 and 7 February 2022. A total of 1468 subjects was included in the study, of whom 36.6% (n = 538) had a positive PCR test for COVID-19. The comparison between fully vaccinated individuals with a booster dose and those without the booster dose revealed a 28% reduction in the odds of infection (OR = 0.719 CI 0.531-0.971). Age (OR = 1.009 CI 1.001-1.018) and low economic status (OR = 1.812 CI 1.416-2.319) were associated with an increased risk of infection. These findings suggest the need for a booster vaccination in the general population to improve the prevention rates of SARS-CoV-2 infection and mitigate severe outcomes.
引用
收藏
页数:11
相关论文
共 41 条
  • [31] Heterologous prime-boost strategies for COVID-19 vaccines
    Sapkota, Binaya
    Saud, Bhuvan
    Shrestha, Ranish
    Al-Fahad, Dhurgham
    Sah, Ranjit
    Shrestha, Sunil
    Rodriguez-Morales, Alfonso J.
    [J]. JOURNAL OF TRAVEL MEDICINE, 2022, 29 (03)
  • [32] SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis
    Ssentongo, Paddy
    Ssentongo, Anna E.
    Voleti, Navya
    Groff, Destin
    Sun, Ashley
    Ba, Djibril M.
    Nunez, Jonathan
    Parent, Leslie J.
    Chinchilli, Vernon M.
    Paules, Catharine, I
    [J]. BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [33] Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
    Tan, C. Sabrina
    Collier, Ai-ris Y.
    Yu, Jingyou
    Liu, Jinyan
    Chandrashekar, Abishek
    McMahan, Katherine
    Jacob-Dolan, Catherine
    He, Xuan
    Roy, Vicky
    Hauser, Blake M.
    Munt, Jennifer E.
    Mallory, Michael L.
    Mattocks, Melissa
    Powers, John M.
    Meganck, Rita M.
    Rowe, Marjorie
    Hemond, Rachel
    Bondzie, Esther A.
    Jaegle, Kate H.
    Baric, Ralph S.
    Schmidt, Aaron G.
    Alter, Galit
    Le Gars, Mathieu
    Sadoff, Jerald
    Barouch, Dan H.
    [J]. JAMA NETWORK OPEN, 2022, 5 (08) : E2226335
  • [34] Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
    Vadrevu, Krishna Mohan
    Ganneru, Brunda
    Reddy, Siddharth
    Jogdand, Harsh
    Raju, Dugyala
    Sapkal, Gajanan
    Yadav, Pragya
    Reddy, Prabhakar
    Verma, Savita
    Singh, Chandramani
    Redkar, Sagar Vivek
    Gillurkar, Chandra Sekhar
    Kushwaha, Jitendra Singh
    Mohapatra, Satyajit
    Bhate, Amit
    Rai, Sanjay Kumar
    Ella, Raches
    Abraham, Priya
    Prasad, Sai
    Ella, Krishna
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [35] who, Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID19) vaccine
  • [36] WHO, SAGE Updates COVID-19 Vaccination Guidance
  • [37] World Health Organization, SINOVAC CORONAVAC CO
  • [38] World Health Organization, Update on omicron
  • [39] World Health Organization (WHO), Colombia Situation
  • [40] The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies
    Xu, Junjie
    Lan, Xinquan
    Zhang, Liangyuan
    Zhang, Xiangjun
    Zhang, Jiaqi
    Song, Moxin
    Liu, Jiaye
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11